Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.23. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Sagimet Biosciences Stock Performance
Shares of SGMT traded down $0.32 during mid-day trading on Friday, reaching $8.73. The stock had a trading volume of 331,606 shares, compared to its average volume of 770,139. The business has a fifty day moving average of $8.18 and a 200 day moving average of $5.11. Sagimet Biosciences has a 12 month low of $1.73 and a 12 month high of $11.41. The firm has a market cap of $267.75 million, a price-to-earnings ratio of -4.96 and a beta of 3.37.
Insider Buying and Selling at Sagimet Biosciences
In other Sagimet Biosciences news, CEO David Happel sold 65,478 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a total transaction of $597,814.14. Following the completion of the transaction, the chief executive officer owned 689,722 shares in the company, valued at $6,297,161.86. This trade represents a 8.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Elizabeth Rozek sold 10,780 shares of the stock in a transaction on Monday, July 21st. The shares were sold at an average price of $9.13, for a total transaction of $98,421.40. Following the transaction, the general counsel owned 183,726 shares of the company's stock, valued at $1,677,418.38. This trade represents a 5.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 84,535 shares of company stock worth $771,805 over the last 90 days. 14.70% of the stock is owned by insiders.
Hedge Funds Weigh In On Sagimet Biosciences
A hedge fund recently raised its stake in Sagimet Biosciences stock. Geode Capital Management LLC raised its holdings in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 0.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 265,324 shares of the company's stock after purchasing an additional 1,600 shares during the quarter. Geode Capital Management LLC owned 0.87% of Sagimet Biosciences worth $2,023,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 87.86% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently weighed in on SGMT shares. Canaccord Genuity Group started coverage on shares of Sagimet Biosciences in a research report on Thursday, July 24th. They set a "buy" rating and a $28.00 target price for the company. Jones Trading upped their target price on shares of Sagimet Biosciences from $15.00 to $27.00 and gave the stock a "buy" rating in a research report on Friday, June 6th. Finally, HC Wainwright started coverage on shares of Sagimet Biosciences in a research report on Thursday. They set a "buy" rating and a $29.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $26.33.
Check Out Our Latest Stock Report on Sagimet Biosciences
About Sagimet Biosciences
(
Get Free Report)
Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
See Also
Before you consider Sagimet Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.
While Sagimet Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
